Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M.sub.4 (mAChR M.sub.4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

A compound of Formula I

##STR00001##

wherein:

ring B is a 5-membered heterocyclic ring, or a 6-membered carbocyclic ring;

each of X.sup.1 and X.sup.2 is independently C, CR, or N, with at least one of them being C;

each of X.sup.3-X.sup.11 is independently C, CR, or N, with at least one of them being N, and two adjacent of X.sup.3-X.sup.7 are carbon-fused to the shown moiety through the linkage indicated by the two squiggly lines;

Y is selected from the group consisting of O, S, Se, NR′, CR′R″, and SiR′R″;

each of R.sup.A and R.sup.B independently represents zero, mono, or up to a maximum allowed substitution to its associated ring;

each of R, R′, R″, R.sup.A, and R.sup.B is independently a hydrogen or a substituent selected from the group consisting of —SiR.sup.1R.sup.2R.sup.3 or —GeR.sup.1R.sup.2R.sup.3, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, with at least one of R.sup.A or R.sup.B comprising —SiR.sup.1R.sup.2R.sup.3 or —GeR.sup.1R.sup.2R.sup.3;

each of R.sup.1, R.sup.2, and R.sup.3 is independently selected from the group consisting of alkyl, aryl group, heteroaryl group, and combinations thereof; and

any two substituents are optionally joined or fused to form a ring where chemically feasible.

A compound of Formula I

##STR00001##

wherein:

ring B is a 5-membered heterocyclic ring, or a 6-membered carbocyclic ring;

each of X.sup.1 and X.sup.2 is independently C, CR, or N, with at least one of them being C;

each of X.sup.3-X.sup.11 is independently C, CR, or N, with at least one of them being N, and two adjacent of X.sup.3-X.sup.7 are carbon-fused to the shown moiety through the linkage indicated by the two squiggly lines;

Y is selected from the group consisting of O, S, Se, NR′, CR′R″, and SiR′R″;

each of R.sup.A and R.sup.B independently represents zero, mono, or up to a maximum allowed substitution to its associated ring;

each of R, R′, R″, R.sup.A, and R.sup.B is independently a hydrogen or a substituent selected from the group consisting of —SiR.sup.1R.sup.2R.sup.3 or —GeR.sup.1R.sup.2R.sup.3, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, with at least one of R.sup.A or R.sup.B comprising —SiR.sup.1R.sup.2R.sup.3 or —GeR.sup.1R.sup.2R.sup.3;

each of R.sup.1, R.sup.2, and R.sup.3 is independently selected from the group consisting of alkyl, aryl group, heteroaryl group, and combinations thereof; and

any two substituents are optionally joined or fused to form a ring where chemically feasible.

The present disclosure provides novel β-arrestin-modulating compounds and methods of making and using same.

The present disclosure provides novel β-arrestin-modulating compounds and methods of making and using same.

Provided herein are compositions and methods for enhancing egress of T-cells from bone marrow of a subject in need thereof. Also provided are compositions and methods for the treatment of diseases characterized by reduced surface display of sphingosine-1-phosphate receptor 1 (S1P1), as well as methods of diagnosis/prognosis related to surface display of SIP 1. Methods of treating cancer are also provided.

There is provided a compound having Formula I, Formula II, or Formula III.

##STR00001##

The variables are described in detail herein.

There is provided a compound having Formula I, Formula II, or Formula III.

##STR00001##

The variables are described in detail herein.

The present disclosure relates to an organic compound represented by Chemical Formula A or B, and an organic light-emitting diode comprising the same.

The present disclosure relates to an organic compound represented by Chemical Formula A or B, and an organic light-emitting diode comprising the same.